南京科佰生物科技有限公司
主營(yíng)產(chǎn)品: atcc代理,ATCC細(xì)胞系,ATCC細(xì)胞株,ATCC細(xì)胞庫(kù)購(gòu)買 |
聯(lián)系電話
南京科佰生物科技有限公司
主營(yíng)產(chǎn)品: atcc代理,ATCC細(xì)胞系,ATCC細(xì)胞株,ATCC細(xì)胞庫(kù)購(gòu)買 |
聯(lián)系電話
參考價(jià) | 面議 |
更新時(shí)間:2023-06-21 16:48:18瀏覽次數(shù):1122
聯(lián)系我們時(shí)請(qǐng)說(shuō)明是化工儀器網(wǎng)上看到的信息,謝謝!
供貨周期 | 現(xiàn)貨 | 規(guī)格 | T-25 Flask |
---|---|---|---|
貨號(hào) | CBP90040 | 應(yīng)用領(lǐng)域 | 生物產(chǎn)業(yè) |
主要用途 | 僅限科研使用 |
Package-RefTM MRD Cocktail Reference Standard | |||||
Cat No. | CBP90040 | ||||
Descripition | MRD是指治療后體內(nèi)殘留的腫瘤細(xì)胞或者標(biāo)志物,通常的翻譯有3種,微小殘留病灶(Minimal Residual Disease)、可檢測(cè)殘留病灶(Measurable Residual Disease)、分子殘留病灶(Molecular Residual Disease)。 | ||||
產(chǎn)品說(shuō)明 | |||||
貨號(hào) | 名稱 | %AF | 規(guī)格 | 濃度 | 備注 |
CBP90040-1 | Package-RefTM MRD Cocktail Reference Standard-0.5% | 0.50% | 500 ng/vial | 20 ng/µL | Optimized ddPCR assay |
CBP90040-2 | Package-RefTM MRD Cocktail Reference Standard-0.05% | 0.05% | 500 ng/vial | 20 ng/µL | Dilution fold-confirmation |
CBP90040-3 | Package-RefTM MRD Cocktail Reference Standard-0.005% | 0.005% | 500 ng/vial | 20 ng/µL | Dilution fold-confirmation |
CBP90040-4 | Package-RefTM MRD Cocktail Reference Standard-0% | 0.00% | 500 ng/vial | 20 ng/µL | ddPCR assay |
MRD-0.5% ctDNA | |||||
GENE | Mut. | CDS change | Variant Classification | AF% | |
EGFR | p.E746_A750delELREA | c.2236_2250del15 GAATTAAGAGAAGCA>- | Pathogenic | 0.69 | |
EGFR | p.S768I | c.2303G>T | Pathogenic | 0.61 | |
EGFR | p.L861Q | c.2582T>A | Pathogenic | 0.61 | |
ERBB2 | p.A775_G776insYVMA | c.2324_2325ins12 ATACGTGATGGC | Pathogenic | 0.41 | |
KRAS | p.G12V | c.35G>T | Pathogenic | 0.39 | |
PIK3CA | p.E542K | c.1624G>A | Pathogenic | 0.62 | |
KRAS | p.Q61H | c.183A>C | Pathogenic | 0.49 | |
EGFR | p.G719C | c.2155G>T | Pathogenic | 0.5 | |
ROS1 | CD74-ROS1 | chr5:149783684:- (hg19) chr6:117646732:- (hg19) | Pathogenic | 0.55 | |
NRAS | p.Q61K | c.181C>A | Pathogenic | 0.41 | |
IDH1 | p.R132C | c.394C>T | Pathogenic | 0.43 | |
FBXW7 | p.R505C | c.1513C>T | Pathogenic | 0.75 | |
KMT2C | p.F4496Lfs*21 | c.13488delA | Likely Pathogenic | 0.46 | |
RAC1 | p.N92I | c.275A>T | Pathogenic | 0.4 | |
BCOR | p.Q1321* | c.3961C>T | Likely Pathogenic | 0.68 | |
BRCA2 | p.M784V | c.2350A>G | Benign | 0.64 | |
ARID1A | p.G1848Wfs*6 | c.5540dupG | Likely Pathogenic | 0.61 | |
CDH1 | p.P126Rfs*89 | c.377delC | Pathogenic | 0.74 | |
BARD1 | p.K208Rfs*4 | c.623delT | Likely Pathogenic | 0.38 | |
BAX | p.E41Rfs*19 | c.121delG | Pathogenic | 0.75 | |
NBN | p.R466Gfs*18 | c.1396delT | Pathogenic | 0.71 | |
KMT2D | p.Q809Rfs*121 | c.2425delG | Likely Pathogenic | 0.51 | |
KMT2D | p.P647Hfs*283 | c.1940delG | Pathogenic | 0.44 | |
QKI | p.K134Rfs*14 | c.401delA | Likely Pathogenic | 0.63 | |
KMT2B | p.W336* | c.1007G>A | Likely Pathogenic | 0.75 | |
NSD1 | p.M1531Cfs*43 | c.4591delA | Likely Pathogenic | 0.74 | |
AXIN1 | p.E31* | c.91G>T | Likely Pathogenic | 0.66 | |
AXIN1 | p.G508Vfs*197 | c.1523del | Likely Pathogenic | 0.69 | |
ARID1B | p.A547Sfs*35 | c.1638_1647del GGGCGGCGGC | Pathogenic | 0.47 | |
HLA-B | p.S101Pfs*37 | c.301_302del | Likely Pathogenic | 0.66 | |
HLA-C | p.V100Efs*38 | c.299_300delTG | Likely Pathogenic | 0.51 | |
TP53BP1 | p.R1447Efs*36 | c.4339delC | Likely Pathogenic | 0.57 | |
POLD1 | N/A | c.E24-2AG>A | Likely Pathogenic | 0.73 | |
CYLD | p.N722Mfs*13 | c.2165delA | Likely Pathogenic | 0.57 | |
INHA | p.G66Afs*61 | c.197delG | Likely Pathogenic | 0.74 | |
RASA1 | p.N838Mfs*4 | c.2513delA | Likely Pathogenic | 0.51 | |
RECQL4 | p.G952Afs*92 | c.2855delG | Likely Pathogenic | 0.54 | |
BRAF | p.V600E | c.1799T>A | Pathogenic | 5.33 | |
ACVR2A | p.K437Rfs*5 | c.1310delA | Likely Pathogenic | 3.98 | |
PIK3CA | p.H1047R | c.3140A>G | Pathogenic | 2.81 | |
BRCA1 | p.D435Y | c.1303G>T | Uncertain significance | 2.53 | |
BRCA2 | p.N1784Tfs*7 | c.5351delA | Pathogenic | 2.35 | |
BRCA2 | p.E2292A | c.6875A>C | Uncertain significance | 1.35 | |
TP53 | N/A | c.783-2A>C | Pathogenic | 1.02 | |
CDKN2A | p.R80* | c.238C>T | Pathogenic | 0.92 | |
HLA-A | p.R45Afs*32 | c.133del | Likely Pathogenic | 1.25 | |
稀釋倍數(shù)驗(yàn)證數(shù)據(jù) | |||||
GENE | Mutation | AF% of MRD-0.5% ctDNA | AF% of MRD-0.05% ctDNA | AF% of MRD-0.005% ctDNA | |
BRAF | p.V600E | 5.33 | 0.54 | 0.047 | |
ACVR2A | p.K437Rfs*5 | 3.98 | 0.40 | 0.038 | |
PIK3CA | p.H1047R | 2.81 | 0.26 | N/A | |
BRCA1 | p.D435Y | 2.53 | 0.24 | N/A | |
BRCA2 | p.N1784Tfs*7 | 2.35 | 0.23 | N/A | |
BRCA2 | p.E2292A | 1.35 | 0.14 | N/A | |
TP53 | c.783-2A>C | 1.02 | 0.11 | N/A | |
CDKN2A | p.R80* | 0.92 | 0.10 | N/A | |
HLA-A | p.R45Afs*32 | 1.25 | 0.11 | N/A | |
Product Information | |||||
Intended Use | Research Use Only | ||||
Unit Size | 4支/套,0.5μg/支,20ng/μL | ||||
Storage | -20℃ | ||||
Expiry | 36 months from the date of manufacture |